SCHEMBL5134701

SCHEMBL5134701

CCCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(CCCC)Cc1c(F)cccc1F

nearest known ligand 0.44

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.39
ALDH1A1 P00352 7/20 0.39
CYP3A4 P08684 6/20 0.39
HPGD P15428 6/20 0.39
HSD17B10 Q99714 6/20 0.39
TSHR P16473 5/20 0.39
PDE4B Q07343 2/20 0.39
C5AR1 P21730 1/20 0.39
TP53 P04637 1/20 0.39
CRHR1 P34998 1/20 0.37
HDAC1 Q13547 1/20 0.35
DRD2 P14416 1/20 0.35
DRD3 P35462 1/20 0.35
ATP4A P20648 1/20 0.35
ATP4B P51164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5074878 0.97 TSHR (0.42) KDM4EALDH1A1CYP3A4HPGDHSD17B10
SCHEMBL5137873 0.95 KDM4E (0.38) KDM4EALDH1A1CYP3A4HPGDHSD17B10
SCHEMBL5136139 0.93 TSHR (0.37) KDM4EALDH1A1CYP3A4HPGDHSD17B10
SCHEMBL5135911 0.93 TSHR (0.39) KDM4EALDH1A1CYP3A4HPGDHSD17B10
SCHEMBL5135270 0.92 KDM4E (0.39) KDM4EALDH1A1CYP3A4HPGDHSD17B10
SCHEMBL5135045 0.91 C5AR1 (0.38) KDM4EALDH1A1CYP3A4HPGDHSD17B10
SCHEMBL5134752 0.90 C5AR1 (0.39) KDM4EALDH1A1CYP3A4HPGDHSD17B10
SCHEMBL5135121 0.90 C5AR1 (0.41) KDM4EALDH1A1CYP3A4HPGDHSD17B10
SCHEMBL5136240 0.89 C5AR1 (0.39) KDM4EALDH1A1CYP3A4HPGDHSD17B10
SCHEMBL5136644 0.89 KDM4E (0.40) KDM4EALDH1A1CYP3A4HPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed